(Total Views: 1100)
Posted On: 11/21/2021 8:37:40 AM
Post# of 153992
Reflecting this morning on how the bashers, shorts 13Ds, BP advocates, and haters must be feeling right now.
Sidley's court victory had to hurt. Must be awaiting the foot to fall with a civil suit.
The Amarex revelation has to cause heartburn. It explains a of of things.
The story about leronlimab "in addition to it's ability to control intrinsic tumor invasion and metastasis as well as inhibit development of supportive tumor microenvironment," That had to hurt.
When Cytodyn initiated it's resubmission of BLA application to FDA for HIV, it had to irritate them.
Then, out of nowhere, Citigroup comes out with a "buy" recommendation. Wow, ouch, where did that come from?
Oh, then there's the Canadian Authorization for Emergency Use for the patient for mTNBC. Oh dear.
On 11/18 there was the Insider Financial article with positive new about Cytodyn. Dammit.
Oh, but we're not done: On 11/19 an article on leronlimab was published by Frontiers in Immunology Journal (reprinted in "The Hottest New"
with very positive news. Crap
Then on the same day out comes a paper by Delvelsight discussing potential HIV treatment.
On 11/20 we read the Seeking Alpha article: "Cytodyn Looking for a Turnaround" Will this ever end?
So, I feel your pain folks. But the sad news for you is that (IMO) this is just the beginning. Oh, by the way, thanks for all the bargain shares the last couple weeks!
Sidley's court victory had to hurt. Must be awaiting the foot to fall with a civil suit.
The Amarex revelation has to cause heartburn. It explains a of of things.
The story about leronlimab "in addition to it's ability to control intrinsic tumor invasion and metastasis as well as inhibit development of supportive tumor microenvironment," That had to hurt.
When Cytodyn initiated it's resubmission of BLA application to FDA for HIV, it had to irritate them.
Then, out of nowhere, Citigroup comes out with a "buy" recommendation. Wow, ouch, where did that come from?
Oh, then there's the Canadian Authorization for Emergency Use for the patient for mTNBC. Oh dear.
On 11/18 there was the Insider Financial article with positive new about Cytodyn. Dammit.
Oh, but we're not done: On 11/19 an article on leronlimab was published by Frontiers in Immunology Journal (reprinted in "The Hottest New"
with very positive news. Crap Then on the same day out comes a paper by Delvelsight discussing potential HIV treatment.
On 11/20 we read the Seeking Alpha article: "Cytodyn Looking for a Turnaround" Will this ever end?
So, I feel your pain folks. But the sad news for you is that (IMO) this is just the beginning. Oh, by the way, thanks for all the bargain shares the last couple weeks!
(42)
(0)
